E‐64c‐Hydrazide Based Cathepsin C Inhibitors: Optimizing the Interactions with the S1’‐S2’ Area
Open Access
- 24 July 2023
- journal article
- research article
- Published by Wiley in ChemMedChem
- Vol. 18 (18) , e202300218
Abstract
The zymogens of the neutrophil serine proteases elastase, proteinase 3, and cathepsin G are converted proteolytically into their pro‐inflammatory active forms by the action of cathepsin C. The inhibition of this cysteine protease therefore is an interesting therapeutic approach for the treatment of inflammatory disorders with a high neutrophil burden such as COPD. Based on E‐64c‐hydrazide as lead structure, we have recently developed a covalently acting cathepsin C inhibitor using a n‐butyl residue attached at the amine nitrogen of the hydrazide moiety to efficiently address the deep hydrophobic S2 pocket. To further optimize the affinity and selectivity profile of this inhibitor, the S1’‐S2’ area was now investigated by a combinatorial approach, showing that Nle‐tryptamide is a ligand superior to the initially used Leu‐isoamylamide. Using the neutrophil precursor line U937 as a cell culture model, this optimized inhibitor blocks the intracellular cathepsin C activity and thereby suppresses the activation of neutrophil elastase.Keywords
This publication has 35 references indexed in Scilit:
- Neutrophil Elastase, Proteinase 3, and Cathepsin G as Therapeutic Targets in Human DiseasesPharmacological Reviews, 2010
- Inhibitors of cathepsin C (dipeptidyl peptidase I)Expert Opinion on Therapeutic Patents, 2010
- (2S,3S)-Oxirane-2,3-dicarboxylic acid: A privileged platform for probing human cysteine cathepsinsJournal of Biotechnology, 2007
- The crystal structure of human dipeptidyl peptidase I (cathepsin C) in complex with the inhibitor Gly-Phe-CHN2Biochemical Journal, 2007
- Neutrophil serine proteases: specific regulators of inflammationNature Reviews Immunology, 2006
- Proteases and lung injuryCritical Care Medicine, 2003
- Proteinases in chronic obstructive pulmonary diseaseBiochemical Society Transactions, 2002
- 2-Nitrophenylcarbamoyl-(S)-prolyl-(S)-3-(2-naphthyl)alanyl-N-benzyl-N- methylamide (SDZ NKT 343), a Potent Human NK1 Tachykinin Receptor Antagonist with Good Oral Analgesic Activity in Chronic Pain ModelsJournal of Medicinal Chemistry, 1998
- Peptide libraries: Determination of relative reaction rates of protected amino acids in competitive couplingsBiopolymers, 1994
- Establishment and characterization of a human histiocytic lymphoma cell line (U‐937)International Journal of Cancer, 1976